Press Releases

· VIAL-TL1A-HLE is a novel, subcutaneous mAb with proprietary half-life extension technology targeting TL1A for a potentially best-in-class treatment for IBD · Preclinical data support the potential for best-in-class dosing interval for patient convenience and efficacy among anti-TL1A therapies · A Phase 1 open-label study in Australia is initiating to evaluate safety, pharmacokinetics, and pharmacodynamic responses in healthy volunteers · Interim subcutaneous safety and pharmacokinetic data from healthy volunteers expected in H2 2025